Tiny but powerful! The good microorganisms encourage us good health but the bad eliminate our life. Because they are invisible to the naked eye, the analysis of these organisms is very challenging. It requires specialized tools and instruments and standardized procedures, especially for harmful microorganisms in food products.
Last year, microbiology laboratories in food factories worldwide were alerted by the new version of ISO 7218: 2024.
Our expert summarizes the main changes for you and it is available to read in this edition of INNOLAB. You can read more examples in the book by scanning the QR code below.
+66 875171651 F +66 2045 5358 innolab@media-matter.com http://www.innolabmagazine.com innolabmagazine
The publisher endeavors to collect and include complete, correct and current information in INNOLAB but does not warrant that any or all such information is complete, correct or current. The publisher does not assume, and hereby disclaims, and liability to any person or entity for any loss or damage caused by errors or omissions of any kind, whether resulting from negligence, accident or any other cause. INNOLAB does not verify any claims or other information appearing in any of the advertisements contained in the magazine, and cannot take any responsibility for any losses or other damages incurred by readers in reliance on such content.
VIV
LARGEST
When it comes to B. cereus, you want to be sure.
Author info วนิดา
Wanida Mukkana
Technical Services Manager
Neogen Asia (Thailand) Co., Ltd. wmukkana@neogen.com
In January 2019, Metro, British news agency reported a case of a college student in Brussels, Belgium who died from food poisoning, after eating pasta that had been left over the refrigerator for 5 days. He had reheated it in the microwave before eating. After half an hour, he had a headache, stomachache, and severe nausea, causing him to vomit for several hours throughout most of the night. However, he was eventually found dead the next morning. The autopsy results showed that he had died from food poisoning caused by Bacillus cereus, and the toxic food in such a large amount that it caused liver failure.
In April 2019, the Thai Food and Drug Administration issued a warning to consumers that a brand of instant boat noodles had been found to be contaminated with B. cereus that exceeded the standard criteria set by the Ministry of Public Health. This caused the product owner to come out and clarify and recall all problematic lots of products. In November of the same year, news broke out about acute food poisoning in nearly 200 students in two junior high schools in rural Chongqing, China. An investigation found that the cause was eating noodles provided by the schools. And the noodles were contaminated with a large amount of B. cereus. The noodles that both schools distributed to students came from the same source and had poor production hygiene management.
From the examples of the incidents that occurred above, it is clear that B. cereus is a pathogen that not only
causes illness to those who are infected, but can also be fatal. When a large number of people are infected with the bacteria or toxins that cause similar illnesses, causing an outbreak, it will certainly have a broad impact on the economy and the credibility of food safety of products, manufacturers, and countries, especially in export products to other countries.
B. cereus is a gram-positive, rod-shaped bacterium that produces spores and toxins. It is often found in the environment, such as soil and water, and is commonly found in plant products such as rice, grains, flour, flour products, spices, animal products, and various flavorings. It is also found in the feces of healthy people, accounting for about 15% of food poisoning cases worldwide. B. cereus is the cause of 1.2% of food poisoning outbreaks worldwide. It can cause two types of food poisoning:
1) Emetic syndrome: Vomiting, caused by the body receiving toxins from the bacteria that are created during growth in food. This toxin is resistant to high temperatures and stomach acidity. Patients experience nausea and vomiting after consuming the toxin for about ½ to 5 hours, and symptoms last no more than 6-24 hours.
2) Diarrhea syndrome: caused by consuming food containing B. cereus cells, which can multiply in the human intestines and produce toxins. The bacteria takes about 8-16 hours to incubate, causing cramps in the abdomen and loose stools. Symptoms usually last no more than 14 hours.
B. cereus is the cause of bloodstream infections or meningitis, which can cause death in some patients. However, some patients may have severe symptoms but are not fatal, but must be hospitalized and may have long-term effects from food poisoning, such as chronic arthritis.
Notification of the Ministry of Public Health, No. 416, 2020 on Prescribing the quality or standard, principles, conditions and methods of analysis for pathogenic microorganisms in foods, has clearly defined food standards for pathogenic microorganisms for each type of food product. For the amount of B. cereus contamination, there are standard criteria in terms of determining the maximum amount that can be detected. which is specified as not more than 50, 100, 200, 500, 1,000 or 2,500 CFU/g, depending on the type of food product. You can find more details at https://food. fda.moph.go.th/food-law/category/ announcement-of-the-ministry-ofpublic-health-1
See the ISO 16140 series for definitions of these performance characteristics.
MPN calculators
https://standards.iso.org/ iso/7218/ed-4/en/
The International standard ISO 7218: 2024: Microbiology of the food chain — General requirements and guidance for microbiological examination is prepared by ISO/TC 34 (ISO: International Organization for Standardization, TC: Technical Committee) Food products, Subcommittee SC 9 Microbiology, in collaboration with the Technical Committee CEN/TC 463 Microbiology of the food chain of the European Committee for Standardization (CEN) under the Technical Cooperation Agreement between ISO and CEN (Vienna Agreement).
The fourth edition (ISO 7218: 2024) specifies the cancellation and replacement of the third edition (ISO 7218:2007), which has been technically revised. It also includes the amendment ISO 7218:2007/Amd 1:2013.
When conducting microbiological tests, it is crucial to detect and/or count only the microorganisms present in the sample—these microorganisms that should not be sourced from the environment. To achieve this goal, good laboratory practices are necessary, including personal hygiene and sterile working techniques that minimize external contamination. This document provides only limited information on the precautions to be taken during microbiological examinations. Therefore, thorough knowledge of microbiological techniques and relevant microorganisms is essential. The test shall be conducted as much safely, accurately, and cautiously as possible, including the inspection and recording of various aspects that may affect the results, the calculation of microorganism numbers, and the assessment of test uncertainty.
The most common risks and controls in microbiology laboratories are outlined in this document. However, the working processes in each laboratory may differ, and a proper risk analysis should be considered to ensure good practice in the laboratory. Periodic assessment and control of critical points can maintain safe and hygienic practices and improve the reliability of test results.
The purpose of this document is to ensure the accuracy of microbiological testing in the food chain. It is particularly to ensure that common testing techniques are consistent across all laboratories to
achieve uniform results in different laboratories, and to ensure the safety of laboratory personnel by preventing the risk of infection. This document includes the key measures necessary for various microbiological tests.
The main changes in the ISO 7218: 2024 standard are as follows:
• The calculations have been simplified, and a calculator has been added (11.3.8: Determination of MPN values using MPN calculators). This article focuses on calculations using the ISO MPN calculator.
• The equipment clauses are reorganized into groups with similar purposes and requirements (Clause 6 equipment and consumables). Since there is no updated academic information, it will not be presented in this article. Laboratories can study it directly from this standard.
• To reduce repetition, cross-references have been added in other general microbiology standards, such as
» Culture media standard (ISO 11133: Microbiology of food, animal feed and water — Preparation, production, storage and performance testing of culture media)
» Method validation (validation: ISO 16140-2: Microbiology of the food chain — Method validation - Part 2: Protocol for the validation of alternative (proprietary) against a reference method, and ISO 16140-4:
Method validation - Part 4: Protocol for method validation in a single laboratory).
» Method verification (ISO 16140-3: Microbiology of the food chain — Method validation — Part 3: Protocol for the verification of reference methods and validated alternative methods in a single laboratory), and
» Uncertainty (ISO 19036: Microbiology of the food chain — E stimation of measurement uncertainty for quantitative determinations) for example.
» The performance characteristics to be determined for validation and verification of reference, alternative and in-house methods, including microbiological confirmation, typing and identification procedures, as well as definitions of the terms are given in the ISO 16140 series, as summarized in Table 1.
• Add information about
» Laboratory quality control (Clause 16 lab quality control in microorganisms)
» Characteristics of controlled microorganisms (Clause 13.4.2 characterization of microorganisms)
» Confirmation and identification methods (Clause 13.1). Many laboratories concern about this clause.
Summary of changes and updates is as follows:
Determining MPN using MPN calculators (Clause 11.3.8)
• It is recommended to use MPN to determine the MPN value from positive and negative tubes, or microplate wells for each dilution.
• The MPN calculators allow input of results from all tests instead of limiting usage to certain dilutions and replications, like the MPN table.
• The results of MPN calculators should include a 95% confidence interval estimate for MPN, along with an indication of the probability of result combination that yields MPN (may be rarity index, rarity categories, or both).
• MPN calculators are specified for use with test portions of 10 g and 100 g. They can be downloaded at: https://standards.iso.org/ iso/7218/ed-4/en/
• The details of the MPN calculators are written in Excel and can be used for serial dilutions up to 10. The details of calculations with Excel spreadsheet macros are presented at the end of this article - a guide to using the ISO MPN Calculators
• Instructions for using the 10 g MPN calculators are available in the link above along with the confirmation document.
• Instructions for using the 100 g MPN calculators, specifically designed for shellfish testing according to ISO 16649-3 (Part 3: Detection and most probable number technique using 5-bromo-4-chloro-3-indolyl-ßD-glucuronide), are included in the general protocol for such tests. They are also available in the link above along with the
confirmation documents.
• Use the positive and negative results from all tubes or wells that have undergone all dilution tests in the MPN calculator to determine the MPN value. It is not appropriate to select a subset of dilutions to determine the value.
Confirmation and identification methods (Clause 13.1)
• Confirmation and identification methods are used to confirm the presumed identification from both qualitative and quantitative methods. Serotyping is used to determine additional characteristics of the relevant presumptive isolation (e.g., pathogenic serotypes).
• The following principles are available for confirming presumptive isolations:
- Confirmation methods that yield positive or negative results (e.g., latex agglutination test, nucleic acid hybridization, and molecular sequencing)
- Methods for identifying serotype identities as confirmation results (e.g., biochemical galleries, mass spectrophotography, and sequencing)
• Use the reference tests specified in specific standards and general confirmation tests as specified in Annex C as an alternative to serological test and biochemical test specified in these standards. Other methods described in this clause may be used unless otherwise specified in the specific standards.
• Any alternative method used must rely on measurement principles (e.g. DNA, protein, immunolocalize, and biologicalbased analysis) that differ from the principles used in detection
or enumeration methods, or must use different markers (e.g., different antibodies and primers). For example, the PCR detection method can be confirmed by another PCR method using different primers or probes to the detection method.
• When using an alternative method in the reference test, verify that it is appropriate as demonstrated by evaluation studies conducted by the manufacturers or published in international scientific literatures, particularly those related to food microbiology.
• A control certificate should be obtained for each batch of tests, specifying the strains used. If the reference test is replaced by another method based on a different principle (e.g., DNA, protein, immunological, biochemical base analysis, or sequencing), refer to the appropriate clause of the ISO 16140 series for details on the validation method.
• The verification of validated alternative methods and serotyping shall require implementation verification according to the appropriate clauses of the ISO 16140 series.
• Only pure cultures should be used for biochemical tests and serological tests. Although it is possible to perform these directly on discrete colonies from selected agar plates in some cases (e.g., ISO 6579-1: Microbiology of the food chain — Horizontal method for the detection, enumeration and serotyping of Salmonella - Part 1: Detection of Salmonella spp.) Uses of mixed cultures may be acceptable if there is sufficient DNA of the target organisms.
Characterization of microorganisms (Clause 14.2)
• General (Clause 14.2.1)
Microorganisms are typically characterized by their phenotypic characteristics. With advancements in molecular testing, microorganisms can now be characterized using such techniques. It is important to note that identification is not always consistent when using both molecular and phenotypic methods. This is because these techniques detect different targets. Molecular techniques detect different targets (such as DNA, RNA, proteins, and carbohydrates), while phenotypic techniques rely on physical characteristics and biochemical reactions of active microorganisms. Additionally, the presence of genes for specific phenotypes does not necessarily mean that those phenotypes are expressed. Therefore, it is important that microorganisms are characterized using techniques suitable for the final applications.
• Phenotypic characterization (Clause 14.2.2)
In general, microorganisms are characterized by their appearance in culture media, microscopic morphology, and reactions to gram's staining, and motility tests. In addition to biochemical tests and serological tests, these characteristics are applied to isolate and identify (and in some cases, classification) targeted organisms in culture-based methods.
• Molecular characterization (Clause 14.2.3)
Microorganisms are characterized by molecular properties (such as DNA, RNA, proteins, and carbohydrate patterns). These molecular characteristics are used to identify and/or characterize target organisms.
Laboratory quality control in microbiology (Clause 16)
Microbiological testing involves several complex procedures, from sampling to calculation and reporting. All of which must be carried out effectively to obtain accurate test results. These procedures are addressed in clauses 4 to 17 of ISO 7218: 2024 and are illustrated in the figure 1– factors affecting the validity of microbiological test results.
Quality control is an essential part of the laboratory quality assurance program to ensure the reliability of test results. The quality assurance program should cover all equipment and consumables, culture media and chemicals, as well as training and competence of personnel.
Quality control at each step of the testing process from start to finish with a specified frequency will ensure the accuracy of test results. Additional key components of the quality assurance program include internal quality control (IQC), which is conducted alongside sample inspection and external quality assessments (EQA) through participation in appropriate proficiency tests (PT).
Internal quality control (Clause 16.2)
• General (Clause 16.2.1)
The main objective of IQC is to ensure that the results are consistent and meet the predetermined criteria. The IQC program should be proportional to the potential impact on accuracy of laboratory results and designed to reflect frequency of tests conducted.
IQC activities help identify tests that are under control or no longer under control. Tests that are out of control should be investigated (root cause analysis), and if necessary, appropriate corrective actions should be conducted.
Process controls (Clause 16.2.2)
• General (Clause 16.2.2.1)
Process control may be conducted alongside routine testing at frequencies scheduled by the laboratory, which may include using blanks. Positive control of target organisms and negative control of non-target organisms or abnormal organisms using culture suspension or spiked samples.
• Blank samples (Clause 16.2.2.2)
Blank samples or sterilized samples from the food chain, which include matrix effects, ensure that culture media and auxiliary materials used are sterile and help maintain aseptic conditions throughout the entire operation. There should be no growth, but low-level contamination may be permitted for counting methods (quantitative) if specific criteria are established.
• Positive control organisms (Clause 16.2.2.3)
Positive control is equivalent to the target organism and creates a general sample group on agar or a positive reaction in broth, and in appropriate cases in confirmatory tests. Positive control is important to demonstrate that the test is conducted correctly. Select positive control microorganisms that can be easily distinguished from general isolated samples. In case of the strains are the foreign species, not known to exist in that region or genetically modified control strains with easily detectable characteristics, such as luminescence or fluorescence.
Note
The use of genetically modified control strains is restricted by certain national or regional regulations. The use of less commonly found and/or genetically modified microorganisms helps reduce risk of false positive results. Detection of these microorganisms in test samples may indicate crosscontamination between strains, and further investigation and retesting of the samples are required before reporting false negative results.
For qualitative method, levels of controlled microorganisms should be close to LOD95 (e.g., 3 to 10 cfu per test portion) to avoid false negatives.
For counting methods using solid medium (pouring or surface spreading), control level of microorganisms should produce a reliable number of colonies on the plate (e.g., 50 to 100). And for counting in liquid mediums using MPN, it should produce a reliable number of positive tubes. Ongoing results can be planned using standard process control charts. Details on the method for preparing low-concentration suspensions are available in ISO 11133 (Microbiology of food, animal feed and water — Preparation, production, storage and performance testing of culture media).
• Negative control organisms (atypical and non-target) (Clause 16.2.2.4)
Atypical and non-target controls can grow on (or in) the test medium but form atypical colonies on agar (or show atypical reactions in broth) and are appropriately confirmed in confirmation tests.
• Negative control organisms (inhibition) (Clause 16.2.2.5)
These negative control microorganisms are inhibited by
the culture medium and are useful in testing the efficacy of the culture medium, but they are rarely included in routine IQC.
• Process control test microorganisms (Clause 16.2.2.6)
Microorganisms used for process control should come from official culture collections or reference laboratories. Strains isolated by the laboratory from general samples can also be used for process control; they shall be well characterized and stable. ISO 11133 covers all aspects of selection, storage, maintenance, and use of test microorganisms for performance testing of culture media and other purposes. ISO 22117: Microbiology of the food chain — Specific requirements and guidance for proficiency testing by interlaboratory comparison, provides guidance on other aspects of quality control materials for microbiology, such as stability and homogeneity.
• Miscellaneous process controls (Clause 16.2.2.7)
Other important points in microbiological inspection should be monitored, such as controlling culture media and controlling time and temperature during incubation, alongside regular testing.
Replicate testing
(Clause 16.2.3)
Mostly, repeated data is used, but in some situations, multiple repetitions may be considered. The results of repeated testing involve conducting tests on different portions of the same sample (split sample). Reference sample or artificial contamination spiked matrices can indicate reproducibility (same condition) and/or reproducibility (different condition) to monitor the performance of laboratory personnel and other objectives.
The data can be included in the estimation of measurement uncertainty for test results as an additional information source (ISO 19036 Microbiology of the food chain — Estimation of measurement uncertainty for quantitative determination).
Spiked samples (Clause 16.2.4)
It is recommended to use spiked samples when the target microorganisms cannot be isolated during testing of general samples. These samples are prepared using both typical and atypical organisms and tested blindly by all laboratory personnel.
The regular program of testing samples with added microorganisms using various matrices, which are often tested in the laboratory, is beneficial for training or updating technicians on general methods. It serves as a supplement to EQA testing, which may not be frequent and is costly.
IQC assessment using control charts (Clause 16.2.5)
Statistical evaluation of IQC data should be conducted for acceptance in quantitative tests. Standard process control charts can be used when there is sufficient data to plot and determine the mean and standard deviation for each test (for example, ISO 11133: 2014 Annex G).
For qualitative tests, accurate long-term monitoring alongside the level of microbial spiking (spiked samples) may be beneficial.
External quality assessment (Clause 16.3)
Participation in proficiency testing (PT) or interlaboratory comparison (ILC) allows users to compare their laboratory performance with other laboratories. When evaluating the results of PT testing, it is important not only to look at each individual score but also to examine various trends to assess and, if necessary, correct any potential biases. The agency conducting the PT test samples should be evaluated by user's laboratories to ensure that test preparations are
appropriate according to ISO/IEC 17043: Conformity assessment - General requirements for the competence of proficiency testing providers for general requirements, and ISO 22117: Microbiology of the food chain — Specific requirements and guidance for proficiency testing by interlaboratory comparison.
Note
Due to the protocol for testing using MPN techniques are various, therefore, to enable laboratories to correctly use the ISO MPN calculators with Excel macro spreadsheets, information from the ISO - International Organization for Standardization document. The results, has been provided for being the practical case studies. For indepth detail, please learn more in the book “Main Changes in ISO 7218: 2024”,written by Pensri Rodma.
A guide to using the ISO MPN Calculators with Excel spreadsheet
macros
1. ISO MPN calculators can be downloaded at http://standards.iso. org/iso/7218/
2. Instructions for using MPN calculators, before using any MPN calculation system, it is necessary to understand the process used in preparing samples for culturing. The MPN calculation depends on the dilution and the volume used in the test. Therefore, the data entered the spreadsheet must reflect this. For example, if the original test sample of 10g is suspended in a 90 mL diluted solution, it will be diluted 1 in 10. Similarly, if a 1 g test portion is suspended in a 4 mL diluted solution, it will be diluted 1 in 5. The volume added in each repeat test may be 1 mL, but it can depend on the situation. Regardless of
actual quantities used, if the correct dilution factor and volumes are input, the results will be MPN per g (or per mL) of the original samples.
3. Steps to use the MPN calculator
Open the Excel macro spreadsheet and insert into the first four cells:
• Experiment name
• Date
• The total number of test sets (up to 18 sets, but for this example, insert 3 sets), and
• Number of dilutions tested (up to 50 sets, but for this example, insert 5 sets)
Number of data fields required (1 field for each trial) will open in the spreadsheet, where the following information should be entered:
• Insert the dilution factor for each dilution (as a decimal) into each cell in column A. For this example, the factor decreases from 0.1 to 0.00001.
• Add volume of the culture (1.0 mL) at each level into the box in column B.
• Enter number of simulated tubes at each level in column C
• Enter number of positive results at each level in column D.
• Then press CTRL+M and the macro will calculate the MPN per g (or mL) of the original sample.
The results will be displayed in a table for all test sets, and a separate field will show the results alongside the input field.
For the input data for sample 1, the obtained MPN is 170/g sample. This result has a rarity value of 0.013, and the same goes for the type 2 result.
4. Different amounts of culture used in each test
• Add the relevant inoculum amount into each cell in column B. Example 2: Add inoculum (10
mL) and press CTRL+M or use the "Calculate Result" button.
Example 3: Add inoculum (0.1 mL) and press CTRL+M or use the "Calculate Result" button.
• The calculation will provide MPN per g for each sample.
• Example 2 with an inoculum of 10 mL, MPN is 17/g. The reason is that the amount of inoculum is more than 10 times, but actual proportion of positive results remains the same as in example 1. Therefore, the MPN obtained reflects the use of an inoculum amount more than 10 times. To adjust the results, it is necessary to multiply the MPN by 10.
• Example 3 with an inoculum of 0.1 ml, MPN is 1,700/g. The reason is that the amount of inoculum is 10 times smaller, but the actual proportion of positive results remains the same as in example 1. Therefore, the MPN result reflects the use of an inoculum 10 times smaller amount. If adjustment of result is needed, it is necessary to divide the MPN by 10.
5. Proceed when the test results are missing
The results from your test set are missing for a set or more, so enter the actual number of tubes you have results for in column C. For example, if the tube at the 10-3 level is lost, enter 4 instead of 5.
The MPN results may vary, but they will not be necessarily changed significantly. The calculated rarity index tends to change, which may cause the categories to change. If the result falls into category 3, the result will be "dimmed" to indicate that it is unacceptable.
6. Simple MPN set with varying test counts
• Set up spreadsheet calculation steps as described above for 2 datasets with 4 levels.
• The example below shows a single volume test (assuming) 10 mL, along with 5 simulations of 1 mL, 0.1 mL, and 0.01 mL.
7. Preparation of dilutions in micro wells
The protocol requires an initial suspension of 1 in 10 ("primary suspension") of the sample (e.g., 25g of sample in 225-mL diluent) before performing and testing further decimal dilutions.
Pipette the primary dilution (A) 2.5 mL into the first three wells. Then transfer 0.5 mL from each well and pipette it into the next three wells, each containing a diluent 2.0 mL. Then repeat this step for further dilutions.
Please note that these dilutions are 1 in 5 (not 1 in 10 as usual). The protocol does not require the removal of 0.5 ml from each final set well.
Additional notes on using MPN calculators
• The MPN value specified in the form of MPN of microorganisms/ mL or /g of test material.
• In the case of the MPN test of micro wells, even though a 25g sample is used in the initial suspension, results should not be reported as MPN/25g. As shown above, the initial test was not inoculated with 25g but diluted 2 in 10 mL, equivalent to 0.2 g. The dilution factor clearly indicates a 1 in 10 dilution and the volume is correctly represented as 2.0 mL. Therefore, there is no need to adjust the calculated MPN/g or /mL.
• It is not statistically correct to state that an MPN of 800/g is equivalent to 20,000/25g, as only 0.2g were tested in each first row of the wells, even though it is mathematically correct.
• For the specified criteria, such as ≤100 organisms/100g, samples of 100g and smaller should be tested instead of multiplying the results obtained by the extra dilution factor. If only smaller samples are tested, the MPN result will be reported as, for example, MPN 0.7/g. This may be mathematically equivalent to approximately 70/100g, but it is not statistically correct.
Article info
ISO 7218:2024: Microbiology of the food chain - General requirements and guidance for microbiological examinations
A guide to using the ISO MPN Calculators: ISO - International Organization for Standardization
2 Quality Procedure (QP)*
3 Work Instruction (WI)
4 Supporting Document (SD)
2 “Quality Procedure”
Quality policy, requirements, organizational chart, etc.
Documents describing the main operational steps of certain activity
Documents describing work instructions in detail or at a layer below layer 2
Forms, supporting documents, indications, reference documents, etc.
P, PM, SP, SOP เป็นต้น
*Note: Layer 2 “Quality Procedure” has various naming depending on the organization, such as P, PM, SP, SOP, for example.
Document management for quality systems is one of the key challenges for laboratories that aim to develop and maintain quality systems according to ISO/IEC 17025 standards. Laboratory personnel often feel that the documents they need to create or manage are too numerous, and they are concerned about how to handle them efficiently, avoid confusion, make them easy to search, ensure they are current (up to date), and prevent overlooking, for example.
Good and systematic documentation is not a burden or as complicated as many think. If we design and manage it properly, it can become a tool that helps laboratory management operate efficiently, reduces errors, and facilitates seamless certification.
Why are documents important in a quality system?
The quality system according to the ISO/IEC 17025 addresses "requirements for competence of testing and calibration laboratories." In the documentation process for this quality system, it will provide:
1. Control the work process to ensure accuracy and consistency.
2. Traceability in reviewing test results.
3. Create reliable evidence for the certification body (reliability).
4. Reduce errors occurring due to non-conformed operations.
However, excessive documentation can become a burden in management. Therefore, laboratories need to employ proper guidelines for document management.
Tips for document management in ISO/IEC 17025
1. Systematic document categories
First, we need to understand that documents in the quality system are generally divided into four layers of hierarchy as shown in the table. Good document categorization helps create clarity, making it easy for reference, retrieving, and connections. At the same time, it will reduce the risk of confusion and redundancy of documents in the quality system.
2. Clearly specify the document codes and versions
A problem that often occurs in laboratories is unintentional use of outdated documents or multiple
versions. Establishing clear document codes ensures that the documents have been properly defined or registered in the system. This makes it easier for us to retrieve documents and reduces confusion from using outdated documents, as well as to update one.
3. Document structure definition
Often, we encounter issues with the hierarchy of documents at layer 2 (QP) and layer 3 (WI). Several volumes have been produced, but the structure of the documents at these layers is not consistent. This inconsistency partly arises from the lack of clear format specifications. How should these documents include, such as objectives, scope, terminology/ definitions, operational procedures, references/related documents, revision history, etc.
Therefore, before creating or writing documents at each layer, a clear and consistent structure should
be established to prevent issues of omission of content and executions under the document.
4. Preparation of the master list of documents
The completed documents are registered by the document controller in the document list. It allows the laboratory to recognize how many documents, what types of documents, and when the documents were created, and what is the latest version of the document, for example. At the same time, the document list itself is a document that allows us to check the links, relationships, document naming, and document codes to see if they are consistent when referred to or used in various documents.
5. Document control
Good document control under the management of the laboratory: distribution shall be appropriately controlled as necessary, regardless of whether the document holders are internal or external personnel. Document control is divided into two categories: controlled documents and uncontrolled documents, with the following characteristics of document usage.
1. Controlled documents are stamped "controlled". When it is revised to a new version, the new document shall be provided to the holder, and the old document shall be retrieved.
2. Uncontrolled documents are stamped "uncontrolled". When it is revised to a new version, the new version is not provided to the holders unless the holders wish to receive the new version.
6. Document reviews
Documents created or revised shall be regularly reviewed by the laboratory at least once a year. The laboratory may review all documents
in the system (administrative or academic) before or after the quality system auditing.
To ensure efficiency and effectiveness of document review, the document holders or creators should conduct the review, as they understand the documents and directly implement it. The management (laboratory manager, quality manager, academic manager, or relevant personnel) should then conduct a verification before confirming that they are usable or needed to update.
At the same time, document review allows the document controller to be aware of the amount (number) of documents in the system, or whether there are duplicate registrations, or there are any vacant document codes, for example.
7. Document destruction
Documents in the quality system have an uncertain lifespan. When documents are updated or discontinued, those documents will expire immediately. In other words, the lifespan of a document depends on whether it has been updated or not. If there are no updates, the document is still valid.
As for the procedure of document destruction, there are several ways, such as shredding, burning, tearing, recycling, etc. Consider as appropriate how important and confidential to the organization and users. If there is a risk of data leakage and they are confidential, reusing would not be an appropriate option for document destruction.
Summary
Documents in almost every quality system have management and administration formats based on the main principles mentioned above. For quality systems according to ISO/ IEC 17025, it may seem like a tough burden. With good management, these documents can become important tools that help laboratories work efficiently, reduce errors, and increase reliability. Good categorization, systematic document control, and the integration of technology into work processes are all approaches that can make document management easier. Document management can be tailored to align with and suit the organization.
Faced with ongoing staff shortages and growing patient demand, healthcare organizations around the world are being compelled to rethink how and where they deliver care. There is also a growing recognition of the importance of reducing the sector’s environmental impact. These 10 healthcare technology trends highlight the potential of innovation to help deliver better care to more people, in a sustainable way.
1. Generative AI: a time-saving virtual assistant
With staff stretched thin, healthcare leaders are turning to automation to reduce the burden on healthcare professionals. The 2024 Philips Future Health Index report showed that 92% of surveyed healthcare leaders think automation is critical for addressing staff shortages by relieving them of repetitive tasks and processes. An equal percentage believe it will save healthcare professionals time by reducing administrative work, allowing them to spend more time with patients.
Generative AI has emerged as a powerful tool supporting this healthcare technology trend, promising to boost clinician productivity in ways that seemed impossible just a few years ago. It’s no wonder that 85% of healthcare leaders worldwide are already investing or plan to invest in generative AI within the next three years. We expect this trend to accelerate in 2025 as the sector continues to explore ways of gaining workflow efficiencies with generative AI.
Already today, generative AI can function as a virtual assistant to save healthcare professionals valuable time, using large language models to organize clinical notes and simplify the ways patient information is communicated across teams. In areas
like cancer care, generative AI could be a game-changer by summarizing vast historical reports to give care teams immediate insights into a patient’s history. It could also speed up reporting and translate complex medical information into common terms, helping to engage patients more in their own care.
2. Simplifying complex diagnostics with AI
While AI can significantly streamline administrative tasks and improve patient engagement, its role in healthcare extends beyond automation. AI can also elevate the skills of healthcare professionals. With experienced staff in short supply in many healthcare systems around the world, AI can help simplify complex diagnostics, enabling less experienced professionals to provide high-quality care with confidence.
For example, recent advances in AI have made cardiac CT easier to use, making it accessible to more facilities to increase capacity and deliver better cardiac care to more people. In addition, less experienced technicians can rely on remote consultations and expert training for virtual support and reassurance. Similarly, embedding AI in ultrasound systems allows physicians to detect, diagnose and monitor cardiac conditions more confidently and efficiently.
Integrating AI into cancer treatments can also enhance patient care by addressing the increased
risk of heart disease associated with therapies such as radiation and chemotherapy. Studies show that adult cancer survivors across a wide range of cancers face a 37% higher risk of developing cardiovascular disease [1] The latest AI technologies can quickly detect signs of cardiotoxicity early in the treatment process by automating and accelerating echocardiographic measurements. Improved reproducibility and shorter study times make the process more efficient and reliable, reducing the risk of treatment delays. That’s good news for cancer patients who may otherwise face serious heart issues alongside their recovery.
3. A silent revolution in surgery
A silent revolution in surgery is marching ahead as minimally invasive procedures continue to replace traditional open surgeries. These minimally invasive procedures are transforming how providers treat cardiovascular conditions, offering patients faster recovery, reduced pain and fewer complications.
With the introduction of new technologies in interventional care, minimally invasive procedures have become more advanced – but also increasingly complex. Physicians need to collect and analyze data from a wide range of sources, such as live 2D X-ray images, 3D ultrasound, Intravascular Ultrasound (IVUS), and FFR or iFR physiological flow measurements, all while closely monitoring the patient. That’s why integration of systems,
software and devices has become increasingly important. This integration allows interventional physicians to treat patients with greater control and confidence during every stage of minimally invasive cardiac procedures.
The latest innovations in imageguided therapy also offer a unique opportunity to expand access to life-saving stroke care. Every two seconds, someone on Earth has a stroke, making it the second leading cause of death and a major cause of long-term disability. Yet less than 5% of our global population has access to mechanical thrombectomy, a minimally invasive treatment that has shown to be highly effective [2] . Expanding access by increasing the number of stroke-ready hospitals and training healthcare professionals in the latest interventional techniques is a cause that Philips is committed to, in partnership with the World Stroke Organization.
4. Seeing the full patient picture in critical care
In critical care, time is crucial –yet always in short supply. Healthcare professionals often lose valuable time pulling patient data together from disparate sources. An open ecosystem approach to patient monitoring can help overcome this challenge by allowing data to flow freely across healthcare technology from different vendors. This creates a unified, standardized patient view that is accessible from anywhere in the hospital.
In 2025, expect further advances in patient monitoring based on this open ecosystem approach to healthcare technology. Medical device integration
and vendor-neutral interoperability in critical care are already helping healthcare organizations improve clinical efficiency and data accuracy, while freeing up staff to focus on providing patient-centered care. Advancing common interoperability standards with industry partners will further enhance this approach, giving systems and devices a common language to ‘speak to each other’ so that patient information can be shared even more easily.
By breaking down data silos, we will also see further development of algorithms that can help care providers predict and prevent adverse patient events. We are just beginning to explore the potential of advanced analytics in critical care, using smart rules to provide care teams with actionable alerts for emerging events. In the future, AI will offer increasingly personalized recommendations by comparing the full patient picture with thousands of similar cases to help determine the best approach for each patient.
5. The home is the new hospital room
While the previous four healthcare technology trends all focus on improving hospital care, there is an equally important trend that will continue to gain traction in 2025: the ongoing shift to managing health outside of the hospital. Hospital-at-home programs for patients who need acute-level care continue to be on the rise, allowing patients to receive high standards of care wherever they are, not just in hospital settings.
Remote patient monitoring plays a critical role in this shift by providing healthcare professionals with real-time data to manage patient care from a distance. It has also been shown to be effective in reducing hospital readmissions for patients with chronic diseases such as congestive heart failure and is increasingly used in post-operative monitoring for early and safe patient discharge. Hospitals get to free up scarce beds for patients who need them more urgently, while patients benefit from an improved experience at home.
In 2025, we will see further advances in AI and predictive analytics to support remote detection of patient health risks based on vital signs and other data. In fact, our 2024 Future Health Index report shows that remote patient monitoring is the biggest area of planned AI implementation over the next three years, with 41% of healthcare leaders intending to invest in it. This will not only help prevent complications and hospitalizations by enabling timely interventions, but also improve quality of life for patients, offering them peace of mind as they receive care in their own homes.
6. Telehealth reaches patients where they are
The use of virtual care soared during the COVID-19 pandemic. Today, it offers an opportunity to change how healthcare is delivered around the world by improving healthcare outcomes, particularly in resourcelimited settings. Bringing care directly to patients in medically underserved communities or regions is an essential part of improving access, equity and affordability of patient care.
From remote patient monitoring and point-of-care ultrasound to realtime video consultations and more, telehealth increases the potential for healthcare to reach more people, no matter where they’re located. It can
also reduce the need for specialist visits, as primary care physicians can resolve 40% of issues with the help of telehealth-based specialists [3] .
For example, telemedicine capabilities allow sonographers and patients based at satellite locations to connect virtually with doctors to discuss ultrasound findings in real time. These more remote locations have every capability of the main practice – without either party needing to drive several hours. Similarly, digitalization, informatics and AI are improving the quality and accessibility of obstetric care in lowincome countries and underserved communities. Interpretation of images obtained through AI-enabled handheld ultrasound is no longer required by the operator, which reduces the training needed to perform the exam.
Telemedicine is now being embraced around the world. For instance, healthcare providers in Indonesia – which faces unique accessibility challenges as the world’s largest country comprised solely of islands – are embracing digital health transformation to improve healthcare accessibility and quality, in line with the government’s healthcare strategy. Telemedicine, remote patient monitoring and AI are among the tools that the country will use to provide patients with care, even in remote areas.
7. Data and digital health are driving tech-savvy parenting
Modern parenting has taken on a decidedly digital flavor with the integration of smart devices and apps into childcare routines. Parents now have unprecedented access to data that can help them make informed decisions and receive reassurance about their child’s overall health and well-being. In fact, there’s growing interest in AI-enabled technologies that not only provide monitoring capabilities but also deliver predictive
insights about a child’s behavioral patterns.
As we move into 2025, we expect an increasing number of parents –particularly first-time parents – to embrace apps and connected devices to help keep a watchful eye on their children. Our research has shown that 80% of parents in the US and 79% of parents in Europe are open to using wearables and smart technologies [4,5] , demonstrating the growing desire to implement care routines based on data to support their children’s safety and health.
Households are becoming more connected through the adoption of smart home systems, allowing parents to conveniently access device features such as video and audio feeds on their phones or computers. Wearables and smart devices like socks, pacifiers and trackers can provide real-time information about a child’s activities or vital signs, including respiratory patterns, body temperature and heart rate. Some AI-enabled baby monitors can help caregivers decode an infant’s cries, allowing for quicker responses to hunger and other needs.
It's clear that digital health tools are transforming modern parenting in remarkable ways. And while these smart technologies aren’t a replacement for active, hands-on caregiving, these devices can offer actionable information, while also giving parents peace of mind.
8. Innovating for sustainability –with sustainable AI
As highlighted in several of the healthcare technology trends above, AI holds immense potential to transform
healthcare, increase efficiency and improve lives. And now, AI is also starting to help improve sustainability for companies – including within healthcare technology.
Healthcare accounts for 4.4% of global CO2 emissions [6] – more than either the aviation or shipping industries. AI could help analyze supply chains and identify areas for improvement, reduce waste, or improve facility management. Operational efficiencies like this are just the start. AI is also already helping to increase imaging speed, translating into lower power consumption per patient scan. How AI can be leveraged to reduce global healthcare emissions and environmental impact is an area ripe with potential for 2025 and beyond.
But along with widespread adoption comes the potential for unintended consequences and significant environmental impact. There’s growing awareness of the need for sustainable innovations and AI models. Healthcare systems are now questioning how AI may be adding to their carbon footprints, while developers are concerned about improving the sustainability of the models.
Why? Because digital solutions need significant energy and materials to generate, process and store data, along with water to cool heat-intensive data centers – all contributing to healthcare’s carbon footprint. In fact, the energy consumption of AI is increasing annually between 26% and 36%, and the power usage of data centers could triple within four years[7]. E-waste is another major issue to consider. Generative AI is
also expected to generate up to 2.5 million tons of e-waste by 2030[8]. As we digitalize healthcare, companies are recognizing that managing and minimizing the energy, material and water needs for AI will be essential to ensure the least impact on the environment.
9. Collaboration to reduce supply chain emissions
The vast majority of healthcare’s carbon footprint – 71% – comes from supply chains through the production, transport and disposal of goods and services[9]. In fact, reducing these Scope 3 emissions is expected to have seven times more impact than just lowering a company’s own emissions. Healthcare organizations are increasingly recognizing the importance of addressing supply chain emissions not just for upcoming government regulations and reducing overall environmental impact, but also for their own financial performance. They are teaming up with partners throughout their value chains to drive change.
Greater transparency and sustainable decision-making are already becoming major considerations in supply chains, from circular product design to collaborations with suppliers. According to the 2024 Future Health Index report, over the next three years, 41% of healthcare leaders plan to choose suppliers with sustainable targets and initiatives, and an equal percentage plan to implement sustainable procurement strategies,
including circular equipment. Some companies like Philips are working directly with their suppliers to ensure they meet environmental standards and adopt sustainable practices. This type of responsible sourcing of goods and services can have a positive ripple effect within the entire healthcare value chain.
Meanwhile, adopting circular practices, which emphasize using less, using longer, and using again, is another way that both healthcare organizations and their suppliers are significantly reducing raw material usage and waste. Refurbishment is one example. Both refurbished consumer products and refurbished medical devices, including image-guided therapy systems and MRI scanners, offer sustainable and cost-efficient alternatives without compromising performance. The refurbished medical devices market is expected to grow from $17.05 billion in 2024 to $30.78 billion by 2029 [10]. By embracing collaborative efforts, healthcare organizations can significantly reduce their environmental impact.
10.
Building resilient healthcare systems with technology to adapt to climate change
As climate change poses increasingly significant challenges, there is an urgent need for hospitals and healthcare systems to enhance their preparedness. The World Health Organization reports that climate change is already impacting health in many ways, including death and illnesses from heat waves, drought,
floods, air pollution, wildfires and more [11]. Many healthcare facilities see increasing numbers of patients with climate-related health issues, yet not all are prepared to care for the influx. Issues extend beyond patient care – healthcare must also consider the impact on their own operations and facilities.
In 2025, as the global conversation turns toward this topic, we expect that healthcare technology will play an important role in ensuring that the healthcare industry is equipped to handle these growing challenges. One way is through developing resilient infrastructure to ensure continuous and effective healthcare delivery, even in the face of climate disasters. This includes transitioning healthcare facilities to renewable energy sources and implementing sustainable practices to reduce their carbon footprint and operational costs.
There are also opportunities for increased training and education programs to equip healthcare providers with the knowledge and skills needed to manage the influx of heat-related illnesses and vector-borne diseases. Additionally, early warning systems could enable prompt responses to minimize health risks, and strengthening community health programs can help improve preventive care and manage climate-sensitive health conditions at the local level.
By embracing such initiatives, the healthcare industry can better adapt to the impacts of climate change and ensure a healthier future for all.
VIV Asia 2025: High-level Seminars on Sustainable Animal Farming, Biosecurity, Disease Prevention and More
With over 150 curated sessions led by 300 industry experts, VIV Asia 2025 provides an unparalleled platform for knowledge-building and networking
VIV Asia 2025, the premier international trade show for the animal protein production and processing industry is set to return this year in co-location with Meat Pro Asia and Horti Agri Next (HAN) Asia, with an expanded focus on sustainable solutions. This year’s edition will feature a series of high-level seminars that will address pressing challenges in modern livestock production, including disease prevention, regenerative agriculture, and biosecurity. These seminars will provide a platform for in-depth discussions, knowledge-
sharing, and collaboration among industry professionals, all with the shared goal of shaping the future of animal farming.
150 seminars, 300 industry experts
With over 150 curated sessions led by 300 industry experts, a major emphasis of VIV Asia 2025 will be on disease prevention and biosecurity, where speakers will present cuttingedge strategies for controlling infectious diseases, mitigating risks, and enhancing farm biosecurity to ensure resilient livestock production. The seminars will offer insights into the latest scientific developments, policy frameworks, and technological innovations designed to protect animal health and minimize the risk of disease outbreaks.
Another key focus will be on regenerative agriculture within animal farming, with thought leaders
exploring sustainable farming practices that enhance soil health, foster biodiversity, and optimize resource efficiency. Discussions will highlight the economic and environmental benefits of regenerative approaches, along with real-world case studies that demonstrate their effectiveness.
Smart tech and alternative protein
The role of smart technologies and precision farming in advancing livestock management will also take center stage. Industry leaders will delve into the transformative impact of artificial intelligence, the Internet of Things (IoT), and automation in improving productivity, optimizing resource use, and reducing environmental impact. Attendees will gain valuable insights into how these innovations can be integrated into existing farming systems to drive efficiency and sustainability.
Feed innovation and alternative protein sources will be another critical topic, with a focus on the latest developments in animal nutrition. Experts will examine alternative feed sources that not only enhance sustainability but also improve animal health and productivity. The discussion will cover advances in feed formulation, nutrient efficiency, and novel protein alternatives.
Conference highlights to watch out for
Among the sessions lined up at VIV Asia 2025, attendees can watch out for these key conferences and plan their schedules accordingly to avoid missing any of the sessions on high demand: Aquatic Conference, AgriBITs, the 1st World Native Poultry Conference, Sustainable Farming Practices and Animal Health: A Pathway to Achieving Agricultural
Climate Mitigation, Functional Feed Innovation and Testing for Aquaculture 2025 (FITA 2025): Shrimp Digestive Health, Shaping the Future of Local Dairy Markets, Biotechnology Innovation for Health Promotion and Sustainability Improvement in Animal Farming, and Smart InsectDriven Feed Solutions for Sustainable Agriculture, among many others! More details regarding the specific locations, dates, and times can be found on the VIV Asia website under the Conference Program section.
All in all, VIV Asia 2025 offers attendees the opportunity to engage with global experts, network with industry leaders, and gain firsthand exposure to groundbreaking technological advancements aimed at revolutionizing the animal protein production sector.
Birgit Horn, Managing Director at VNU Europe shares, “VIV Asia 2025
represents a critical opportunity for industry stakeholders to access the latest knowledge, exchange ideas, and collaborate on innovative solutions that will shape the future of animal farming. These high-level seminars and conferences will provide an unparalleled platform for discussing the challenges and opportunities that lie ahead, ultimately contributing to a more sustainable and resilient industry.”
Don’t miss VIV Asia, Meat Pro Asia, and Horti Agri Next Asia 2025 from March 12–14, 2025, at IMPACT, Bangkok, Thailand! Onsite registration costs €15 or THB 600. Register online for **Free Admission** before March 11, 2025 at: www. vivasia.nl / www.meatpro-asia.com / www.hortiagrinext-asia.com
Vietnam Economy
Vietnam’s economic landscape is poised for resurgence, forecasting a substantial GDP growth of 6.9% in 2024. A projected GDP growth rate of 5.8% solidifies its position as a regional powerhouse. Forecasts from the Mid-term Economic Overview Report 2019 predict a sustained growth of approximately 7% from 2021 to 2025, with the added projection of reaching a GDP per capita of $4,500 by 2025.
Chemical industry
The Vietnam’s chemical industry is upward-bound, anchored by the strategic “Vietnam Chemical Industry Development Strategy 2030.” Envisaging an impressive average growth rate of 10%-11% by 2030, the sector is poised for a transformative journey. The industry’s appetite for advanced technologies and global integration hints at substantial growth potential. Notably, opportunities lie in optimizing technology adoption and labor productivity to drive industry progression.
Pharmaceutical industry
Vietnam’s pharmaceutical landscape attract foreign investment due ot cost-efficient labor and production advantanges. Collaborative ventrues between international and domestic
players harness Vietnam’s potential as a high-value pharmaceutical production hub. With an ambitious target to achieve $1 billion in pharmaceutical exports by 2030, the sector presents sighnificant growth potential. Vietnam ranks among the world’s fastest-growing pharmaceutical markets.
analytica Vietnam 2025
The country’s largest and most influential trade fair for laboratory technology, analysis, and biotechnology, is set to return bigger than ever. Taking place from 2-4 April 2025 at the Saigon Exhibition and Convention Center (SECC), Ho Chi Minh City, this 8th edition will be the largest in the event’s history, expanding to two exhibition halls and welcoming over 300 exhibitors and brands, and 6,000 trade visitors from across the region.
Endorsed by the Ministry of Science and Technology in Vietnam and supported by the National Agency for Science and Technology Information (NASATI), Center for Science and Technology Information (CESTI), Key Laboratory of Analytical Technology for Environmental Quality and Food Safety Control (KLATEFOS), VNU, Federal Ministry for Economic Affairs and Climate Action of Germany, and the Association of Small & Medium Enterprises (Singapore), analytica
Vietnam 2025 continues to uphold its reputation as a leading industry event.
Global Participation and Networking Opportunities
This year’s edition will see extensive global participation, with dedicated pavilions from Germany, Singapore, and China, alongside exhibitors from Vietnam, Malaysia, Japan, South Korea, the UK, Switzerland, France, Spain, Turkey, India, and the USA. The event continues to serve as a premier platform for networking, innovation, and business development in the industry.
Michael Wilton, Managing Director of MMI Asia, the organizer of analytica Vietnam, expressed, “The continuous growth of analytica Vietnam reflects the increasing demand for advanced laboratory and analytical solutions across Vietnam and the region. Expanding to two halls not only accommodates more exhibitors but also opens up new avenues for collaboration, knowledge exchange, and innovation. We’re excited to welcome professionals from all over the world to experience our largest and most comprehensive edition yet.”
What to Expect at analytica Vietnam 2025?
• Academic Conference:
Learn from internationally renowned experts as they share research, trends, and findings on topics such as Environmental and Green Chemistry, Food and Quality Control, Pharmaceutical Analysis & Health Science, and Future Technologies.
• Live Lab Demo: This interactive feature brings advanced analytical instruments, automation, and testing procedures to life, allowing visitors to witness real-time applications across various industries.
• Innovation Zone: A dedicated area showcasing the newest and most groundbreaking products in laboratory technology, analysis, and biotech solutions.
• Lab 4.0 Exhibitor Forum: Explore a range of innovative technologies and solutions transforming laboratory operations. Topics will include automation, digitalization, advanced data analytics, new materials, and cutting-edge techniques in laboratory management and research.
• Lab Design and Construction Forum: Gain insights into the latest trends in lab design, energy-efficient solutions, sustainable practices, and innovative layouts. Industry experts and renowned speakers will share their expertise on creating modern laboratories that meet both functionality and environmental standards.
• Lucky Draw: Stand a chance to win exciting prizes sponsored by our esteemed exhibitors.
• Hosted Buyer Program: The largest program yet, with
key buyers from Vietnam, Cambodia, Thailand, and Malaysia, invited for exclusive business meetings with exhibitors.
Vincent Au Yeong, Country Manager of ITS Vietnam, the event’s Bronze Sponsor, shared, “As a customer of analytica Vietnam for nearly 10 years, I have witnessed the event’s growth and the valuable benefits it brings each year. The continuous development of analytica has reinforced our confidence in its ability to provide insights, foster partnerships, and stay ahead of industry trends. We’re proud to be part of this long-term journey and look forward to further growth together. We can’t wait to meet both our longtime and new customers here.”
Top 15 Products You Can Look Forward to Seeing at the Exhibition:
1. Mixer Mill MM 400 by ITS
2. PacBio Revio/Onso Sequencing System by DKSH
3. Xevo MRT Mass Spectrometer by Waters
4. Liquid Chromatograph Mass Spectrometer by Shimadzu
5. epMotion 5075 by Eppendorf
6. Biosafety cabinet, Tangerine by Oriental Giken
7. High-Speed Amino Acid Analyzer LA8080 by 2H Instrument
8. EMC Magnetic Cell Holder by EMCLAB Instruments GmbH
9. Hot Head by ELDEX CORPORATION
10. Gas generator for TOC Gas Analysis by cmc Instruments GmbH
11. Sykam Amino Acid Analyzers by Hoa Viet Co., Ltd
12. SCIEX ZenoTOF 7600 SCIEX ZenoTOF 7600 LC-MS/MS System Model: ZenoTOF 7600 by Viet Nguyen Co.,ltd
13. Avio 550 ICP-OES - Perkin Elmer
14. MIRI Time-Lapse Incubat by ESCO
15. AI - RIDA ®SMART APP Allergen (2024) by R-Biopharm
Be Part of analytica Vietnam 2025 – Register Today!
To make the most of your experience at analytica Vietnam 2025, we recommend that trade visitors register in advance. This will ensure seamless access to the event and provide updates on the latest developments. For more information and to complete your registration, please visit www.analyticavietnam2025. events-regis.com/
BUILDING A SUSTAINABLE FUTURE TOGETHER AT PROPAK ASIA 2025
ProPak Asia 2025 is set to return as a pivotal event in the dynamic world of processing and packaging, a sector constantly evolving due to technological advancements, changing consumer behavior, and increasing emphasis on sustainability. As the premier exhibition for processing and packaging in Asia, this event is recognized as a must-attend for industry professionals who need to stay ahead of the curve, discover innovative solutions, and engage in meaningful discussions on industry trends.
Entering its 32nd edition, ProPak Asia has steadily grown in importance over the years. It is not just an exhibition; it serves as a key platform for networking, investment, and industry collaborations. In 2025, the event will once again offer attendees the opportunity to explore cuttingedge developments in a wide range of sectors, including packaging and processing technology, pharmaceuticals, logistics, material handling, cold chain, and more. Attendees will be exposed to the latest trends and innovations shaping the future of the industry, all under one roof.
Following the remarkable success of ProPak Asia 2024, which saw over 68,000 visitors and more than 2,000
exhibitors from 42 countries, the upcoming event promises to build on this momentum. Whether they are a startup, SME, or established enterprise, ProPak Asia 2025 will provide invaluable insights and business opportunities. The exhibition will feature eight industryfocused zones: ProcessingTechAsia, PackagingTechAsia, DrinkTechAsia, PharmaTechAsia, Lab&TestAsia, PackagingSolutionAsia, Coding, Marking&Labelling Asia, and Coldchain, Logistics,Warehousing& FactoryAsia. Each zone is designed to cater to specific market needs, offering comprehensive solutions that address the entire supply chain, from processing and packaging to logistics and warehousing.
In addition to the exhibition, ProPak Asia 2025 will host a series of highly anticipated activities and seminars. Building on the popularity of past events, highlights will include the Global Packaging Forum, executive talks on future industry trends and sustainability, the Future Food, and specialized zones like Design Box and Lab&Test Theatre. These sessions will offer participants the chance to engage with thought leaders and stay up to date on critical developments in the industry.
Sustainability will take center stage at ProPak Asia 2025, with a renewed focus on environmentally friendly practices. The event’s theme, “Carbon-Neutral Pathways to a Sustainable Processing and Packaging Ecosystem,” reflects the growing global demand for more sustainable business practices. With increasing pressure from both customers and governments, businesses must adapt sooner rather than later to benefit in every dimension. ProPak Asia aims to provide a platform where companies can explore carbon-neutral solutions, paving the way toward a more sustainable future.
Set to take place from 11 to 14 June 2025, at BITEC in Bangkok, ProPak Asia 2025 will occupy Halls 98-104, offering exhibitors and visitors a rich environment for exploring innovations and creating business opportunities. As much more than just an exhibition, ProPak Asia continues to foster a thriving community where the industry can invest, grow, collaborate, and transform together.
For more information about the show, please visit www.propakasia. com
For further information, please contact nednapa.l@informa.com.
Anh Thư Founder, Research Manager Grandpa’s Garden Institute for Cosmetic Science Studies thudo@grandpasgarden.org
Innovative Formula Silver Winner: HA-Zn & Collagen Soothing Oil-control Cooling Gel by Bloomage Biotechnology Corp
A Carbopol® Ultrez 30 Polymer
Biobloom™ Micro-ecobeauty ME-3
Innovative Formula Gold Winner: Shine Control Moisture Fusion Fluid with Ectoin Natural by Bitop
Aristoflex Eco T Caesalpinia Spinosa Gum / Ammonium AMPS Crosspolymer
in-cosmetics Asia exhibition (held from November 5 to 7, 2024) has concluded, highlighting six breakthrough ingredients featuring innovative technologies and concepts, along with three cosmetic formulations selected from various applications presented by participating global cosmetic ingredient companies.
The Innovative Ingredients category was divided into two subcategories: Active Ingredients and Functional Ingredients. Each subcategory honored the top three entries with gold, silver, and bronze awards, acknowledging their contributions to the world of cosmetic science.
Active Ingredients
Gold Winner: Neuroglow™ by Givaudan
The highest award in active ingredients this year goes to a tanning agent. Neuroglow™ mimics the beneficial properties of sunlight, stimulating production of melanin (+126%) and promoting the skin’s release of wellbeing molecules such as beta-endorphin (+43%), vitamin D (+345%) and oxytocin (+229%). By boosting melanin production, Neuroglow™ prepares the skin for sun exposure, allowing for a
faster, healthier, more natural and better protected tan. What’s more, it improves general wellbeing and energy levels at the same time as preventing potential inflammatory damage caused by the sun.
Neuroglow’s activity include:
● Prepares the skin for a healthy sun exposure
● Boosts the production of protective melanin, protanning
● Boosts wellbeing and energy
● Prevents sun-driven inflammation damage and promotes DNA protection
Neuroglow™ is crafted by green fractionation from Persicaria tinctoria, and is sourced from Provence in France.
Silver Winner: Baolift™ by Vytrus Biotech
Exercise enhances muscle tone and overall well-being. Imagine achieving similar benefits for your
skin—without a workout.
Baolift™ is the breakthrough anti-aging ingredient inspired by the Fit-Skin concept. At its core is the Skin-Fascia-Muscle axis, a dynamic network where skin and muscle cells communicate, mimicking the effects of exercise. Baolift™ activates this axis using exerkines—key biomolecules that improve muscle tone and rejuvenate skin for a lifted, radiant appearance.
Derived from African baobab stem cells, Baolift™ delivers a rich metabolome of terpenes, polyphenols, and proteins, pioneering the innovative Plant Workout Factor for advanced skincare.
Baolift™’s applications include: formulations to decrease under eye bags, V-lifting treatments, strengthening & toning formulas to reduce sagging.
Bronze Winner: Pantodium Cica by Codif TN
Pantodium Cica is an organic fermented seaweed extract that activates the epidermal regeneration process for multifactorial effectiveness: moisturizing, repairing damaged skin and optimizing the healing process. It encourages the production of natural vitamin B5 by the skin, providing a natural and stable alternative to synthetic D-panthenol.
Pantodium Cica’s unique mechanism leverages the microbiota to synthesize vitamin B5 at optimal physiological doses, creating a personalized synergy—the Pantodium B5 complex. This ensures tailored benefits for each individual, regardless of age or skin type.
For daily use, Pantodium Cica is effective at 0.5%, making it suitable for a variety of products to hydrate dry skin, soothe sensitive skin, and maintain a healthy, glowing complexion. When used at 1%, it significantly helps reduce acne scars, sun damage, and hyperpigmentation. At 2%, it offers deep tissue repair, ideal in a repairing balm, for improving the skin’s healing process.
Functional Ingredients
Gold Winner: Pickmulse™ by Lucas Meyer
Pickmulse™ is an ingredient from an innovative patented technology. Being a starch extracted from organic quinoa grains, it could either be used as a surfactant-free emulsifier in a cold process emulsion, or an encapsulation system for lipophilic ingredients in a hot process preparation.
When cold processed (under 40°C), Pickmulse™ easily forms pickering emulsions: it surrounds the oil droplets to create surfactant-free and microbiome friendly emulsions.
Furthermore, Pickmulse™ leaves on the skin surface an invisible yet soft and powdery film.
In a hot process, Pickmulse™ is able to create capsules of lipophilic ingredients by fusing quinoa starch particles at increased temperature (of around 55 - 60°C). It allows an easy and cost-efficient in-house encapsulation of any lipophilic ingredients, including active ingredients, oils, UV filers, and fragrances.
Silver Winner: Wilsol SPF Booster by
Wilmar
Launched in April 2024, Wilsol SPF Booster is a plant-based, biodegradable ingredient that uniquely multiplies the sun protection factor (SPF) performance of ultraviolet (UV) filters by up to three times. It is compatible with mineral and chemical sunscreens, across water-in-oil and oil-in-water emulsion systems. This efficacy and formulation flexibility allows producers of beauty products to reduce UV filter usage, thereby optimising cost, protection and sensory performance.
In a burgeoning sunscreen care market that seeks balance between sun protection and environmental safety,
Wilsol SPF Booster is a pioneering solution that meets these needs.
Bronze Winner: Dynasan CrystalCONTROL L by IOI Oleo GmbH
Dynasan® CrystalCONTROL L is an innovative ingredient designed to eliminate the blooming effect—a common issue in lipstick production caused by the polymorphic behavior of waxes and triglycerides. (Polymorphism is when a substance crystallizes into different structures, which can lead to white spots appearing in formulations).
Completely polymorphic-free, Dynasan ® CrystalCONTROL L maintains a stable crystalline structure, preventing blooming and ensuring consistent quality. It simplifies production by reducing reprocessing efforts, supports sustainability, and enhances brand image. Additionally, it improves glide, moisturizes skin, strengthens the barrier, and is compatible with natural waxes, oils, pigments, and preservatives. Vegan and COSMOS-compliant, Dynasan® CrystalCONTROL L is the ultimate solution for efficient, high-quality color care formulations.
Innovative Formula
Gold Winner: Shine Control Moisture Fusion Fluid with Ectoin Natural by Bitop
This emulsion provides soothing and anti-inflammatory effects and is suggested to use for skincare and suncare purposes. It features Ectoin natural - a lab-grown powerhouse active ingredients that is proven to be highly-effective and multifunctional (for anti-aging, anti-pollution, blue light protection, long term hydration, skin repair, anti-inflammatory and microbiome support).
Procedure:
1. Mix Phase A and heat up to 70°C while stirring
2. Mix Phase B separately and heat to 80°C
3. Mix Phase A into B under an overhead stirrer
4. Add Phase C individually under an overhead stirrer
5. Homogenize for 3 minutes
6. Adjust the pH to 4.50 with Lactic acid
Properties:
- pH = 4.5
- Viscosity = 177.6 mPas (200 rpm)
- Fluid gel-like texture, bright white appearance
Silver Winner: HA-Zn & Collagen
Soothing Oil-control Cooling Gel by Bloomage Biotechnology Corp
This gel-based formula focuses on oil control and mattifying effects. It features Hybloom Zinc Hyaluronate (HA-Zn), a combination of zinc ions and hyaluronic acid through coordination bonding, delivering the beneficial properties of both HA and zinc. The preparation process of HAZn is eco-friendly, straightforward, and efficient, resulting in high zinc content, low sodium ion residue, and excellent stability.
Hannah Yuan, the creator of the silver-winning recipe, explains the properties of HA-Zn and other active ingredients in her formula.
In vivo tests have demonstrated that HA-Zn offers moisturizing and skin-soothing benefits, helps regulate sebum secretion, reduces oxidative skin damage, and supports overall skin health maintenance.
Procedure:
1. Mix Phase A and dissolve completely
2. While stirring phase A, add phase B mixture and stir evenly
3. Premix phase C, mix evenly, then pour into the AB mixture, stir until dissolved, add phase D, and continue stirring until all materials are completely dissolved
As global warming escalates temperatures and UV radiation, skin suffers accelerated collagen loss and discoloration. The bi-phase Thermal Aging AGELESS Mist, powered by the patented smart dipeptide SYN-UP,
tackles these issues with clinically proven result:
- Makes the skin more resilient against stress day-by-day with visible reduction of flakiness and redness
- Down-regulates melanin synthesis leading to even skin tone and age spot reduction
- Significantly increases collagen up to 78% with visible improvement of skin elasticity and wrinkle reduction
Procedure:
1. Prepare Phase A by adding in ingredients sequentially and mixing till homogenous
2. Adjust pH of phase A to target 5.0 if necessary
3. Prepare Phase B by mixing till homogenous
4. Add phase B to Phase A
Properties:
pH = 4.5 – 5.5
Conclusion
My impression of this year's exhibition is that the cosmetic ingredients industry is evolving in a way that greatly facilitates the work of cosmetic formulators. There are now many multifunctional or multi-purpose ingredients that can protect and promote skin health and aesthetic look while complying with various global standards (such as vegan, halal, China compliant), as well as being environmentally friendly. Meeting all these criteria is undoubtedly a challenge for ingredient suppliers. I look forward to seeing further advancements in the cosmetic ingredients industry at the in-cosmetics Asia 2025.
analytica Vietnam 2025
SUBSCRIPTION FORM
Fill out your detail or attach your business card
Subscription Date .................................................................................. Where did you find us? ................................................................................
Your name Your job title
Your e-mail Your mobile number .......................................................................................
Company name
Company address
......................................... Zip code ........................................ Website Tel no. ........................................... Fax no. ..........................................
Name and address on receipt □ Same as above □ Other, please specify
Your industry (please select your interest by inputting ü)
Please remit payment to MEDIA MATTER Co., Ltd., savings account number 1082280729, Siam Commercial Bank Pcl. The swift code is SICOTHBK. Please send the pay-in slip via fax number +66 2878 1026 or innolab@media-matter.com
